Cytori Therapeutics DE (NASDAQ:CYTX) Could Burn Your Long Portfolio After More Shorts

August 1, 2017 - By Michael Collier

 Cytori Therapeutics DE (NASDAQ:CYTX) Could Burn Your Long Portfolio After More Shorts

The stock of Cytori Therapeutics DE (NASDAQ:CYTX) registered an increase of 9.58% in short interest. CYTX’s total short interest was 1.51 million shares in August as published by FINRA. Its up 9.58% from 1.38M shares, reported previously. With 384,500 shares average volume, it will take short sellers 4 days to cover their CYTX’s short positions. The short interest to Cytori Therapeutics DE’s float is 6.84%.

The stock decreased 4.83% or $0.022 on July 31, reaching $0.442. About shares traded. Cytori Therapeutics Inc (NASDAQ:CYTX) has declined 65.60% since August 1, 2016 and is downtrending. It has underperformed by 82.30% the S&P500.

Cytori Therapeutics, Inc. is a biotechnology firm engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The company has market cap of $14.34 million. The Firm develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It currently has negative earnings. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation.

Cytori Therapeutics Inc (NASDAQ:CYTX) Ratings Coverage

Among 5 analysts covering Cytori Therapeutics (NASDAQ:CYTX), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Cytori Therapeutics has $1000 highest and $1.50 lowest target. $5.31’s average target is 1101.36% above currents $0.442 stock price. Cytori Therapeutics had 9 analyst reports since August 8, 2015 according to SRatingsIntel. Maxim Group maintained Cytori Therapeutics Inc (NASDAQ:CYTX) rating on Saturday, August 8. Maxim Group has “Buy” rating and $5 target. The firm earned “Buy” rating on Wednesday, May 31 by Maxim Group. On Monday, July 24 the stock rating was maintained by Maxim Group with “Buy”. The company was downgraded on Tuesday, July 25 by B. Riley & Co. The rating was upgraded by Zacks on Friday, September 4 to “Hold”. Maxim Group maintained Cytori Therapeutics Inc (NASDAQ:CYTX) rating on Monday, July 10. Maxim Group has “Buy” rating and $1000 target. The stock of Cytori Therapeutics Inc (NASDAQ:CYTX) has “Buy” rating given on Monday, August 10 by TH Capital.

More notable recent Cytori Therapeutics Inc (NASDAQ:CYTX) news were published by: Streetinsider.com which released: “Cytori Therapeutics (CYTX) Says AMA Approves New Category III CPT Codes …” on July 10, 2017, also Streetinsider.com with their article: “Cytori Therapeutics (CYTX) Issued Key Patents for Scleroderma” published on July 06, 2017, Zacks.com published: “Are Options Traders Betting on a Big Move in Cytori Therapeutics (CYTX) Stock …” on July 07, 2017. More interesting news about Cytori Therapeutics Inc (NASDAQ:CYTX) were released by: Streetinsider.com and their article: “Cytori Therapeutics (CYTX) STAR Trial of Habeo Cell Therapy in Patients with …” published on July 24, 2017 as well as Marketwatch.com‘s news article titled: “Cytori Therapeutics’ stock plunges toward record low after stock offering …” with publication date: April 11, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.